SEATTLE, Washington, February 8, 2021— The Life Sciences Discovery Fund (LSDF) today announced nearly $600,000 in awards to support commercial development of technologies to improve the diagnosis and management of major health conditions. Two of the four new grants are aimed at producing novel tests to diagnose or monitor disease...
Read more
In July 2012, Nexgenia scientist Barrett J. Nehilla presented his work at the NanoBio Seattle conference here in Seattle, WA. Using HIV-1 p24 antigen as a model system, he outlined exciting data that showed faster immunoassay times with Nexgenia’s polymer-based nanotechnology compared to commercially available magnetic microparticles. A link to..
Read more
In April 2012, Nexgenia CEO Thomas Schulte attended the American Association for Clinical Chemistry (AACC) Oak Ridge Conference: Emerging Technologies for 21st Century Clinical Diagnostics, which was held in San Jose, CA. He presented a poster that outlined the advantages of Nexgenia’s reagents for diagnostics and other life sciences applications...
Read more
